Ad Header



The Pulse of the Pharmaceutical Industry

FDA approves fast-acting insulin Fiasp

Written by: | | Dated: Friday, September 29th, 2017


U.S. FDA approves Novo Nordisk fast-acting insulin Fiasp


(Reuters) – The U.S. Food and Drug Administration on Friday approved Novo Nordisk’s fast-acting insulin to treat diabetes.

The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. It is already approved in Canada and Europe.

Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co’s Humalog and Novo Nordisk’s own NovoLog, known as NovoRapid outside the United States.

Last year the FDA declined to approve the product and requested additional information.


Reporting by Toni Clarke in Washington; Editing by Chizu Nomiyama


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation